Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bazedoxifene hydrochloride (TSE-424) 是一种 IL-6/GP130蛋白相互作用抑制剂,可用于胰腺癌的研究。它也是一种有口服活性的,能透过血脑屏障的,非甾体、选择性的雌激素受体调节剂 (SERM),对 ERα 和 ERβ 作用的 IC50值分别为 26 nM 和 99 nM,可用于研究骨质疏松症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 713 | 待询 | ||
5 mg | ¥ 1,279 | 待询 | ||
10 mg | ¥ 2,304 | 待询 | ||
25 mg | ¥ 3,591 | 待询 | ||
50 mg | ¥ 6,461 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,304 | 待询 |
Bazedoxifene hydrochloride 的其他形式现货产品:
产品描述 | Bazedoxifene hydrochloride (TSE-424) is a novel, non-steroidal, indole-based estrogen receptor modulator (SERM) binding to both ERα and ERβ with IC50 of 23 nM and 89 nM, respectively. |
靶点活性 | ERβ:89 nM, ERα:23 nM |
体外活性 | Bazedoxifene is a third generation selective estrogen receptor modulator (SERM). Bazedoxifene does not stimulate ERα mediated transcriptional activity and acts as an antagonist to estradiol in cultured breast cancer (bMCF-7) cells. Similar results are seen in other cell lines including CHO (ovarian), HepG2 (hepatic) or GTI-7 (neuronal) with bazedoxifene having no ERα agonist activity and acting as an antagonist to estradiol action.[2] Bazedoxifene does not stimulate proliferation of MCF-7 cells but did inhibit 17β-estradiol-induced proliferation with IC50 of 0.19 nM. [3] |
体内活性 | In an immature rat model, bazedoxifene increases uterine wet weight 35% at a dose of 0.5 mg/kg compared to an 85% increase with raloxifene at the same dose and a 300% increase in uterine weight with ethinyl estradiol at a dose of 10 μg/kg. Ovarectomized rats treated with 0.3 mg/d bazedoxifene displayed maintenance of bone mass and bone strength similar to effects seen with 2 μg/d ethinyl estradiol, 3 mg/d raloxifene, or sham operated animals. [2] |
激酶实验 | Ligand binding competition experiments: Test compounds are initially solubilized in DMSO and the final concentration of DMSO in the binding assay is ≤ 1%. Eight dilutions of each test compound are used as an unlabelled competitor for [3H]17β-estradiol. Typically, a set of compound dilutions would be tested simultaneously on human, rat and mouse ER-α and ER-β. The results are plotted as measured DPM vs. concentration of test compound. For dose-response curve fitting, a four parameter logistic model on the transformed, weighted data are fit and the IC50 is defined as the concentration of compound decreasing maximum [3H]estradiol binding by 50%. For active compounds, the IC50 is determined at least three times. It should be noted that IC50 values are not direct measures of a ligand's affinity for the receptor. Rather, they can only be compared as relative values, in this case to 17β-estradiol. |
细胞实验 | For the proliferation assay, cells are plated at 20,000 cells/well in a 24-well plate in DMEM/F12 (50:50) (phenol red-free) with 10% charcoal/dextran-treated FBS and 1 × GlutaMAX-1. After overnight incubation, the medium is aspirated and treatments in DMEM/F12 (50:50) (phenol red-free) with 2% charcoal/dextran-treated FBS and 1 × GlutaMAX-1 are added to the wells. Each plate has a vehicle (baseline proliferation) and treatments. Treatments included 10 pM 17β-estradiol determined to be the EC80 for 17β-estradiol and 17β-estradiol in combination with six concentrations of BZA. Treatments from d 1 are renewed on d 3 and d 6 by aspirating medium from wells and replacing with fresh medium and treatments. On d 7, cells are detached from the plate using trypsin-EDTA and counted using a Multisizer II.(Only for Reference) |
别名 | Bazedoxifene HCl, 盐酸巴多昔芬, TSE-424 |
分子量 | 507.06 |
分子式 | C30H34N2O3·HCl |
CAS No. | 198480-56-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: <1 mg/mL
Ethanol: <1 mg/mL
DMSO: 93 mg/mL (183.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9722 mL | 9.8608 mL | 19.7215 mL | 49.3038 mL |
5 mM | 0.3944 mL | 1.9722 mL | 3.9443 mL | 9.8608 mL | |
10 mM | 0.1972 mL | 0.9861 mL | 1.9722 mL | 4.9304 mL | |
20 mM | 0.0986 mL | 0.493 mL | 0.9861 mL | 2.4652 mL | |
50 mM | 0.0394 mL | 0.1972 mL | 0.3944 mL | 0.9861 mL | |
100 mM | 0.0197 mL | 0.0986 mL | 0.1972 mL | 0.493 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bazedoxifene hydrochloride 198480-56-7 Endocrinology/Hormones Estrogen Receptor/ERR Estrogen/progestogen Receptor interactions TSE424 ERβ IL-6/GP130 STAT3 SERM Inhibitor selective estrogen Bazedoxifene Hydrochloride protein-protein receptor TSE 424 Bazedoxifene HCl ERα modulator 盐酸巴多昔芬 inhibit TSE-424 Bazedoxifene inhibitor